New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?


Journal

Neoplasma
ISSN: 0028-2685
Titre abrégé: Neoplasma
Pays: Slovakia
ID NLM: 0377266

Informations de publication

Date de publication:
May 2022
Historique:
received: 07 02 2022
accepted: 04 04 2022
pubmed: 27 4 2022
medline: 10 6 2022
entrez: 26 4 2022
Statut: ppublish

Résumé

The value of serum tumor biomarkers used for lung cancer diagnosis is still controversial in clinical practice. This study aimed to further dissect and evaluate the clinical value of serum progastrin-releasing peptide (ProGRP), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCC-Ag), carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA21-1) together with a potential new biomarker, the human epididymis protein 4 (HE4) for lung cancer diagnosis, in a large cohort of a Chinese population. Ostensibly healthy individuals, as well as those with benign non-cancerous diseases, benign tumors, lung cancers, and other types of malignancies, were enrolled in the study. Serum ProGRP, NSE, SCC-Ag, CEA, CYFRA21-1, and HE4 were analyzed using the chemiluminescence immunoassay. Data were analyzed utilizing the SPSS and GraphPad Prism software. Detailed dissection of the diagnostic characteristics of serum 6 biomarkers on lung cancer was performed. All 6 biomarkers showed capabilities in characterizing lung cancer from other diseases. ProGRP and NSE were highly specific to small cell lung cancer (SCLC); SCC-Ag was a fair biomarker for NSCLC, specifically SCC histotype; CEA showed specificity to SCLC, followed by NSCLC; CYFRA21-1 was a good biomarker for both SCLC and NSCLC; HE4 showed high specificity to SCLC. For NSCLC characterization, CYFRA21-1+HE4+CEA was the best combinatory pattern in the terms of diagnostic performance (AUC=0.8110). The best combinatory analysis for SCLC was ProGRP+NSE+HE4 (AUC=0.9282). Patients with advanced stage, larger tumor, males, and age 50 or older had higher serum biomarkers levels than those with early stage, smaller tumor, females, and age under 50. Six biomarkers had capabilities in characterizing lung cancer with high or fair diagnostic performance. HE4 is a potential biomarker for both SCLC and NSCLC diagnosis, which merits further investigation.

Identifiants

pubmed: 35471981
doi: 10.4149/neo_2022_220207N144
pii: 220207N144
doi:
pii:

Substances chimiques

Antigens, Neoplasm 0
Biomarkers, Tumor 0
Carcinoembryonic Antigen 0
Keratin-19 0
WAP Four-Disulfide Core Domain Protein 2 0
WFDC2 protein, human 0
antigen CYFRA21.1 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

729-740

Auteurs

Ming Li (M)

Department of Laboratory Diagnostics, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.

Yi Zhang (Y)

Department of Laboratory Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China.

Li Jiang (L)

Department of Laboratory Medicine, Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.

Yan Li (Y)

Department of Laboratory Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.

Gang Li (G)

Department of Laboratory Medicine, Henan Provincial People's Hospital, Zhengzhou, Henan, China.

Jianping Zhou (J)

Radioimmunoassay Center, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.

Chen Yang (C)

Department of Laboratory Medicine, Suzhou Hospital Affiliated to Nanjing Medical University, Suzhou, Jiangsu, China.

Xinhui Li (X)

Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Wei Qu (W)

Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.

Yong Chen (Y)

Division of In Vitro Diagnostics, Shenzhen Mindray Bio-Medical Electronics Corporation, Shenzhen, Guangdong, China.

Qing Chen (Q)

Division of In Vitro Diagnostics, Shenzhen Mindray Bio-Medical Electronics Corporation, Shenzhen, Guangdong, China.

Shukui Wang (S)

Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.

Jinliang Xing (J)

State Key Laboratory of Cancer Biology, Department of Physiology and Pathophysiology, Fourth Military Medical University, Xi'an, Shaanxi, China.

Huayi Huang (H)

Division of In Vitro Diagnostics, Shenzhen Mindray Bio-Medical Electronics Corporation, Shenzhen, Guangdong, China.
Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH